No material corporate-specific disclosures were identified for Merck & Co. in the 30 days preceding this report's generation date of 2026-06-25. The most prominent macro development in the period was the reported interception of Iranian missiles aimed at US military forces in Kuwait, as covered by CNBC, which introduced uncertainty into broader market conditions. US Central Command confirmed the incident, which threatened existing ceasefire arrangements and elevated geopolitical risk sentiment across equity markets during the period [Brief - 2026-06-17] [Brief - 2026-06-09] [Brief - 2026-06-01].
For the trailing twelve months ending 2026-03-31, Merck & Co. recorded revenue of $65.77 billion, representing year-over-year growth of 4.87%. Net income for the same period was $8.94 billion, yielding a net margin of 13.59%. Operating margin stood at 0.56%. Earnings per share declined 185.57% year-over-year on a TTM basis. The company held $5.33 billion in cash against total debt of $49.12 billion. The stock traded at a price-to-earnings ratio of 33.97 [SEC 10-Q - MRK - 2026-03-31].
This report was triggered by material changes in institutional ownership disclosed in recent 13F filings. Citadel reduced its MRK position by 7%, AQR Capital reduced its position by 23%, and Millennium reduced its position by 55% [SEC 13F - Citadel - Q1 2026] [SEC 13F - AQR Capital - Q1 2026] [SEC 13F - Millennium - Q1 2026]. No insider transaction data was available for the current reporting period.
The 10-year US Treasury yield stood at 4.50% and the 2-year yield at 4.16%, producing a normal yield curve spread of 34 basis points [FRED DGS10] [FRED DGS2]. This configuration reflects the prevailing interest rate environment in which Merck's debt obligations and capital allocation decisions are situated as of the report generation date.